The U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to sever ...

The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...

More than half (53%) of patients reached remission after one year of Omvoh treatment and 46% experienced healing of the ...

An elemental diet is a medical protocol that replaces food and drinks with liquid formula for people with serious GI ...

Jane Searfoss was inspired to become a child life specialist at Boston Children's Hospital because of her own experience ...

Wearable devices can identify, differentiate, and predict flare-ups, or the worsening of symptoms and inflammation, in inflammatory bowel disease (IBD), Mount Sinai researchers have shown in a ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory ...

Mirikizumab is a humanized immunoglobulin G4 monoclonal antibody that selectively binds to the p19 subunit of human interleukin (IL)-23.

The clearance broadens use of Omvoh, which is part of a slate of new medicines Lilly is counting on to build on its success ...

According to new research, wearables like an Apple Watch or an Oura smart ring can detect the symptoms and predict flare-ups of chronic bowel inflammatory woes.

This story is part of our ongoing “First Steps” series, where we share extraordinary stories of men who transformed their bodies, minds, and lives with a focus on the first steps it took them to get ...